GlassScriptPhysician profile
Barry D Schair
NPI 1023289774
$9,391.41
in general payments reported to CMS, 2019-2025
45 companies · $1,439 in 2025
The $1,439 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,229 · 2020: $911 · 2021: $1,622 · 2022: $1,333 · 2023: $1,095 · 2024: $1,763 · 2025: $1,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,197 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,197.46 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,056.52 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,045.24 | 2019-2025 | |
| Boston Scientific Corporation | $772.60 | 2019-2025 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $715.12 | 2019-2025 | Farxiga, Andexxa |
| Janssen Pharmaceuticals, INC | $632.84 | 2019-2024 | Xarelto |
| Pfizer INC. | $590.78 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $579.91 | 2019-2024 | |
| Medtronic, INC. | $437.67 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $417.13 | 2021-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $320.60 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.11 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $284.75 | 2019-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $202.34 | 2020-2025 | Amvuttra, Onpattro |
| Abbott Laboratories | $201.10 | 2021-2025 | Mitraclip |
| Lundbeck LLC | $151.05 | 2019-2021 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $145.84 | 2020-2021 | |
| Novo Nordisk INC | $135.19 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Baxter Healthcare | $129.28 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Esperion Therapeutics, INC. | $124.70 | 2021-2025 | Nexletol |
| Amarin Pharma, INC. | $111.86 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $98.81 | 2022-2025 | |
| Cvrx, INC. | $96.03 | 2024-2025 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $73.06 | 2023-2024 | Inpefa |
| Impulse Dynamics (USA) INC. | $71.51 | 2022-2025 | Optimizer, Optimizer |
| Regeneron Healthcare Solutions, INC. | $71.06 | 2019 | |
| Bridgebio Pharma, INC. | $70.55 | 2025 | Attruby |
| Janssen Scientific Affairs, LLC | $68.37 | 2022 | |
| Arbor Pharmaceuticals, INC. | $66.29 | 2019-2022 | |
| Atricure, INC. | $59.10 | 2022-2024 | |
| Kiniksa Pharmaceuticals, LTD. | $54.32 | 2021-2023 | Arcalyst |
| Medline Industries LP | $48.32 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $38.10 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $33.59 | 2024 | Arcalyst |
| Daiichi Sankyo INC. | $29.86 | 2019-2023 | Injectafer |
| Irhythm Technologies, INC. | $19.68 | 2022 | |
| Tactile Systems Technology INC | $18.95 | 2020 | |
| Lilly USA, LLC | $18.09 | 2025 | Zepbound |
| Actelion Pharmaceuticals US, INC. | $16.37 | 2023 | Opsumit |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Glaxosmithkline, LLC. | $14.73 | 2025 | Shingrix, Arexvy |
| Acarix USA INC. | $14.56 | 2023 | Cadscor System |
| Allergan, INC. | $14.09 | 2019 | |
| G Medical Diagnostic Services, INC. | $13.25 | 2022 | |
| Preventice Services, LLC | $12.26 | 2019 | |
| Medicure Pharma INC. | $11.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Schair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.